Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||MK-1454 + Pembrolizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|MK-1454||STING1 Agonist 8||MK-1454 is an agonist of the stimulator of interferon genes protein (TMEM173, STING1), that when activated leads to the release of cytokines that stimulate cytotoxic T lymphocytes to enhance the anti-tumor immune response (Ann Oncol, Oct 2018, 29 (suppl 8), abstract LBA15, PMID: 31355488).|
|Pembrolizumab||Keytruda||MK-3475||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 63||Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous squamous cell carcinoma, MSI-H or dMMR or TMB high advanced solid tumors, PD-L1 expressing NSCLC, gastric and GEJ adenocarcinoma, squamous esophageal carcinoma, and cervical cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC, with axitinib in RCC, and with Lenvatinib in endometrial carcinoma that is not MSI-H or dMMR (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||MK-1454 + Pembrolizumab||Phase I||Actionable||In a Phase I trial, MK-1454 in combination with Keytruda (pembrolizumab) resulted in partial response in 24% (6/25) and a disease control rate of 48% (12/25) in patients with advanced solid tumors (Ann Oncol, Oct 2018, 29 (suppl 8), abstract LBA15; NCT03010176).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03010176||Phase I||MK-1454 + Pembrolizumab MK-1454||Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)||Recruiting|
|NCT04220866||Phase II||MK-1454 + Pembrolizumab Pembrolizumab||Study of Intratumoral (IT) MK-1454 in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)||Recruiting|